bearish
Celltrion (068270 KS): Competition Makes US Approval of New Oncology Biosimilar Unappealing
124 Views30 Sep 2022 00:45
SUMMARY
- Celltrion Inc (068270 KS) has recently received FDA approval for Vegzelma, a biosimilar to the reference product Avastin (bevacizumab), for the treatment of multiple types of cancer.
- Apart from Celltrion, FDA has already approved three Avastin biosimilars. With increasing competition, ASP for the market leader Mvasi in the U.S. declined 39% y/y and 21% q/q in 2Q22.
- Despite being present in the U.S. oncology biosimilar market for quite a long time, Celltrion has not been able to gain dominant market share for its existing products.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Retrospectively Reviewing Prop Traders Vs. Retail on T±4 Ex-Date29 Dec 2022
- Celltrion Siblings Announced Dividends: Trading Based on Past Patterns17 Dec 2022
- Celltrion Group Companies - Sharp Increase in Dividends17 Dec 2022
- Celltrion (068270 KS): Competition Makes US Approval of New Oncology Biosimilar Unappealing30 Sep 2022
- Celltrion (068270 KS): Muted Q1 2022 Performance Reflects Continuing Biosimilars Pricing Pressure14 May 2022
- Celltrion (068270 KS): Increasing Biosimilar Competition- Main Concerning Factor09 Mar 2022
x